Grant: Engage Grants Program
University of Guelph
$24,984.00
Evaluating immuno-modulatory phytoglycogen nanoparticles for enhanced production of newcastle disease virus
EF 2017-18
Résumé
Viruses engineered to express antigens to promote a protective immune response against a particular pathogen(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essentialtools used in the prevention and treatment of human and animal disease. However, a considerable impedimentto the production of viruses as vaccines or therapeutic agents is the cost of manufacturing. The goal of thisproject is to test whether Phytoglycogen nanoparticle (PhG) technology from Mirexus can be used as a cellculture additive to dramatically increase viral vaccine vector production. Mirexus is a leadingbio-nanomaterials company based in Ontario that produces phytoglycogen nanoparticles with valuableperformance characteristics that are currently leveraged across a wide variety of personal care applications.While traditionally PhG has been marketed to the cosmetic and food industries, Mirexus is rapidly developingPhG-based technologies for the biomedical and pharmaceutical industries. Preliminary results indicate that aproprietary modification of PhG (immune-modulating-PhG, IM-PhG) enhances in vitro virus production andthis effect is conserved between cell lines derived from fish to humans and both aquatic and mammalianviruses, including a 1000-fold enhancement of influenza virus production. To grow their business and expandtheir applications platform, Mirexus is seeking to investigate whether IM-PhG can be used as a cell cultureadditive to boost production of viral vaccines. Although Mirexus has the expertise to synthesize and modify thePhG, they do not have the infrastructure (e.g. BSL 2 laboratory, access to viruses) or the virology expertisenecessary to conduct these experiments. The purpose of this Engage grant is to facilitate collaboration betweenMirexus and an academic virology lab that can evaluate whether the above mentioned enhancing effect extendsto the production of Newcastle Disease Virus, an industrially important vaccine vector for animal health, inmammalian cells and embryonated eggs. As Mirexus is a Canadian company, expansion of its applicationsplatform should lead to increased demand for this patented technology and more high tech jobs for Canadians.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
522188-2017
Name nom
Wootton, KSarah
Department département
Pathobiology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
24984
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Partie
1
Nb partie
1
Application title
Evaluating immuno-modulatory phytoglycogen nanoparticles for enhanced production of newcastle disease virus
Keyword
NSERC
Application summary
Viruses engineered to express antigens to promote a protective immune response against a particular pathogen(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essentialtools used in the prevention and treatment of human and animal disease. However, a considerable impedimentto the production of viruses as vaccines or therapeutic agents is the cost of manufacturing. The goal of thisproject is to test whether Phytoglycogen nanoparticle (PhG) technology from Mirexus can be used as a cellculture additive to dramatically increase viral vaccine vector production. Mirexus is a leadingbio-nanomaterials company based in Ontario that produces phytoglycogen nanoparticles with valuableperformance characteristics that are currently leveraged across a wide variety of personal care applications.While traditionally PhG has been marketed to the cosmetic and food industries, Mirexus is rapidly developingPhG-based technologies for the biomedical and pharmaceutical industries. Preliminary results indicate that aproprietary modification of PhG (immune-modulating-PhG, IM-PhG) enhances in vitro virus production andthis effect is conserved between cell lines derived from fish to humans and both aquatic and mammalianviruses, including a 1000-fold enhancement of influenza virus production. To grow their business and expandtheir applications platform, Mirexus is seeking to investigate whether IM-PhG can be used as a cell cultureadditive to boost production of viral vaccines. Although Mirexus has the expertise to synthesize and modify thePhG, they do not have the infrastructure (e.g. BSL 2 laboratory, access to viruses) or the virology expertisenecessary to conduct these experiments. The purpose of this Engage grant is to facilitate collaboration betweenMirexus and an academic virology lab that can evaluate whether the above mentioned enhancing effect extendsto the production of Newcastle Disease Virus, an industrially important vaccine vector for animal health, inmammalian cells and embryonated eggs. As Mirexus is a Canadian company, expansion of its applicationsplatform should lead to increased demand for this patented technology and more high tech jobs for Canadians.